CellPhire Therapeutics key facts
as of Oct 2026- Operator of a clinical-stage biotechnology company intended to design long shelf-life platelet-derived therapeutics.
- CellPhire Therapeutics is valued at approximately $105.3M as of Oct 2026 (last reported valuation).
- It has raised $51.2M; the latest was Later Stage VC ($5.0M) in Dec 2025.
- Notable investors include United States Department of War, Keiretsu Forum, TEDCO, Simcah Management, Circadian Ventures — 9 tracked in total.
- Status: Privately Held (backing).
CellPhire Therapeutics's last reported valuation, Mar 2021. Nothing priced has surfaced since.
- ·Watch CellPhire Therapeutics: the Monday email on marks, rounds and moves
CellPhire Therapeutics funding rounds
No funding rounds for CellPhire Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
CellPhire Therapeutics valuation
CellPhire Therapeutics's last reported valuation was $105 million in Mar 2021. No priced round, secondary trade or fund mark has surfaced since.
CellPhire Therapeutics investors
9 investors are on record for CellPhire Therapeutics, including United States Department of War, Keiretsu Forum, TEDCO and Simcah Management.
About CellPhire Therapeutics
Operator of a clinical-stage biotechnology company intended to design long shelf-life platelet-derived therapeutics. The company's technology has applications that have potential applications in healthcare fields, from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine, to clinical and research diagnostic reagents, enabling physicians to maintain an adequate supply while treating bleeding casualties.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2005
- Employees
- 48
- Website
- cellphire.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.